147 related articles for article (PubMed ID: 15478598)
1. Advances in taxane therapy for metastatic breast cancer.
ONS News; 2004; 19(9 Suppl):75-6. PubMed ID: 15478598
[TBL] [Abstract][Full Text] [Related]
2. Association of CYP1B1 with hypersensitivity induced by taxane therapy in breast cancer patients.
Rizzo R; Spaggiari F; Indelli M; Lelli G; Baricordi OR; Rimessi P; Ferlini A
Breast Cancer Res Treat; 2010 Nov; 124(2):593-8. PubMed ID: 20632082
[TBL] [Abstract][Full Text] [Related]
3. Paclitaxel and docetaxel in the treatment of breast cancer.
Saloustros E; Mavroudis D; Georgoulias V
Expert Opin Pharmacother; 2008 Oct; 9(15):2603-16. PubMed ID: 18803448
[TBL] [Abstract][Full Text] [Related]
4. Phase II study of weekly albumin-bound paclitaxel for patients with metastatic breast cancer heavily pretreated with taxanes.
Blum JL; Savin MA; Edelman G; Pippen JE; Robert NJ; Geister BV; Kirby RL; Clawson A; O'Shaughnessy JA
Clin Breast Cancer; 2007 Dec; 7(11):850-6. PubMed ID: 18269774
[TBL] [Abstract][Full Text] [Related]
5. Taxanes in the treatment of breast cancer: a prodigy comes of age.
Miller KD; Sledge GW
Cancer Invest; 1999; 17(2):121-36. PubMed ID: 10071597
[TBL] [Abstract][Full Text] [Related]
6. Taxanes in elderly breast cancer patients.
Wildiers H; Paridaens R
Cancer Treat Rev; 2004 Jun; 30(4):333-42. PubMed ID: 15145508
[TBL] [Abstract][Full Text] [Related]
7. Chemotherapy-induced amenorrhea from adjuvant breast cancer treatment: the effect of the addition of taxanes.
Davis AL; Klitus M; Mintzer DM
Clin Breast Cancer; 2005 Dec; 6(5):421-4. PubMed ID: 16381625
[TBL] [Abstract][Full Text] [Related]
8. Paclitaxel in early breast cancer: a viewpoint by David A. Cameron.
Cameron DA
Drugs; 2004; 64(16):1848-9. PubMed ID: 15301567
[No Abstract] [Full Text] [Related]
9. Managing taxane toxicities.
Markman M
Support Care Cancer; 2003 Mar; 11(3):144-7. PubMed ID: 12618923
[TBL] [Abstract][Full Text] [Related]
10. Successful docetaxel rechallenge with cromoglycate after major sensitivity reactions.
Westermann AM; ten Bokkel Huinink WW; Rodenhuis S
Ann Oncol; 1996 Jan; 7(1):104. PubMed ID: 9081381
[No Abstract] [Full Text] [Related]
11. [nab-Paclitaxel. Clinical value of an innovative taxane-containing formulation].
Lipp HP
Med Monatsschr Pharm; 2013 Jan; 36(1):14-24. PubMed ID: 23379109
[TBL] [Abstract][Full Text] [Related]
12. [The action and toxicity of taxanes].
Lipp HP; Bokemeyer C
Pharm Unserer Zeit; 2005; 34(2):128-37. PubMed ID: 15803797
[No Abstract] [Full Text] [Related]
13. Quality-of-life considerations with taxane-based therapy in metastatic breast cancer.
Maxwell C
Clin J Oncol Nurs; 2013 Feb; 17 Suppl():35-40. PubMed ID: 23360701
[TBL] [Abstract][Full Text] [Related]
14. Use of gabapentin in the prevention of taxane-induced arthralgias and myalgias.
Nguyen VH; Lawrence HJ
J Clin Oncol; 2004 May; 22(9):1767-9. PubMed ID: 15118009
[No Abstract] [Full Text] [Related]
15. Taxanes as a first-line systemic treatment in metastatic breast cancer.
Urquhart LM
Clin J Oncol Nurs; 2013 Feb; 17 Suppl():15-21. PubMed ID: 23360699
[TBL] [Abstract][Full Text] [Related]
16. Paclitaxel and docetaxel in breast and ovarian cancer.
Drug Ther Bull; 1997 Jun; 35(6):43-6. PubMed ID: 9282422
[TBL] [Abstract][Full Text] [Related]
17. nab-paclitaxel: a novel formulation of taxane for treatment of breast cancer.
Vishnu P; Roy V
Womens Health (Lond); 2010 Jul; 6(4):495-506. PubMed ID: 20597612
[TBL] [Abstract][Full Text] [Related]
18. Docetaxel (Taxotere) for advanced breast cancer.
Med Lett Drugs Ther; 1996 Sep; 38(984):87-8. PubMed ID: 8828520
[No Abstract] [Full Text] [Related]
19. Doxorubicin and paclitaxel, a highly active combination in the treatment of metastatic breast cancer.
Dombernowsky P; Gehl J; Boesgaard M; Paaske T; Jensen BV
Semin Oncol; 1996 Oct; 23(5 Suppl 11):23-7. PubMed ID: 8893895
[TBL] [Abstract][Full Text] [Related]
20. Docetaxel (Taxotere): an overview of first-line monotherapy.
Trudeau ME
Semin Oncol; 1995 Dec; 22(6 Suppl 13):17-21. PubMed ID: 8604448
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]